RECEIVED CENTRAL FAX CENTER OCT 2 9 2009

Application No. 10/557,283

Page 3

Docket No.: 61383(71699)

AMENDMENTS TO THE CLAIMS

- Claim 1. (Currently Amended) A method of determining whether a subject is at risk for developing atheroselerosis-associated plaque rupture or myocardial infarction comprising:
- a) measuring the level of <u>Apolipoprotein C-1 (ApoCI)</u> protein in a biological sample from the subject; and
- b) comparing the level of ApoCI protein in the biological sample from the subject to the level of ApoCI protein from a control,

wherein the subject is human, and wherein an increased level of ApoCI protein in the biological sample as compared to the control sample indicates that the subject is at increased risk for developing atherosclerosis-associated plaque rupture or myocardial infarction.

- Claim 2. (Currently Amended) The method of claim 1, wherein the protein is associated with elevated large ApoCI enriched HDL levels.
- Claim 3. (Original) The method of claim 2, wherein the elevated large HDL is ApoCl-enriched.
- Claim 4. (Currently Amended) The method of claim 1, wherein the level of LDL in the <u>biological</u> sample is normal.
- Claim 5. (Previously Presented) The method of claim 1, wherein the subject is female.
- Claim 6. (Previously Presented) The method of claim 1, wherein the subject has been previously diagnosed with atheroselerosis.
 - Claim 7. (Cancelled)

Application No. 10/557,283 Page 4 Docket No.: 61383(71699)

Claim 8. (Previously Presented) The method of claim 1, wherein the biological sample is selected from blood, serum, and plasma.

Claims 9-38. (Cancelled)

- Claim 39. (New) A method of determining whether a subject is at risk for developing atherosclerosis-associated plaque rupture or myocardial infarction comprising:
- a) measuring the level of ApoCI enriched HDL in a biological sample from the subject; and
- b) comparing the level of ApoCI enriched HDL in the biological sample from the subject to the level of ApoCI enriched HDL from a control.

wherein an increased level of ApoCI enriched HDL in the biological sample as compared to the control sample indicates that the subject is at increased risk for developing atheroselerosis-associated plaque rupture or myocardial infarction.